drugset / Trial / NCT01825395

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

NCT01825395

Expanded access Approved for marketing University of Colorado, Denver

Summary

To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amifampridine Small molecule